Treatment Of Breast Cancer Using Combination Therapies Comprising Gdc-9545 And Gdc-0077
Patent No. EP4294395 (titled "Treatment Of Breast Cancer Using Combination Therapies Comprising Gdc-9545 And Gdc-0077") was filed by Genentech on Feb 14, 2022. The application was issued on Mar 26, 2025.
Patent Summary
Combination therapies comprising GDC-9545 (or its pharmaceutically acceptable salts) and GDC-0077 are provided for treating estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) locally advanced breast cancer (laBC) or metastatic breast cancer (mBC). Treatment methods include administering both agents once daily (QD) on days 1–28 of one or more 28-day cycles, specifically in regimens of 30 mg GDC-9545 and 9 mg GDC-0077 for 2 to 72 cycles. These therapies aim to inhibit tumor growth, produce tumor regression, and increase overall survival, progression-free survival, and clinical benefit rates compared to controls, while potentially reducing adverse events like hepatotoxicity and hyperglycemia. Patients may be screened for ER, PR, Ki67, or PIK3CA mutations.
Patent Family
Patent Oppositions
Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.
Dossier Documents
The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.
Date
Description
EP4294395
- Application Number
- EP22713478A
- Filing Date
- Feb 14, 2022
- Status
- Granted And Under Opposition
- Feb 21, 2025
- Publication Date
- Mar 26, 2025
- External Links
- Slate, Register , Google Patents